Xiaoming has a track record of discovering and developing bona fide new molecular entities. Prior to joining Velocity Pharmaceutical Development, He cofounded Theron Pharmaceuticals, a preclinical stage company developing a best-in-class bronchodilator for the treatment of COPD and uncontrolled asthma. He was previously the Senior Director of Chemistry at CoMentis Inc. In this capacity, he spearheaded cognition research effort targeting Alzheimer's disease and cognitive deficit associated with schizophrenia. Previously, Dr. Zhang served as Director of Medicinal Chemistry at Millennium Pharmaceuticals, Portola and ARYx, where he successfully led the discovery and preclinical development of a number of new molecular entities, notably elinogrel and tecarfarin. Earlier in his career, Dr. Zhang was a research scientist and later program leader at Roche, where he successfully led the alpha1a adrenergic agonist program, culminating in the discovery of R1484 which was evaluated in the clinic for stress incontinence.
Dr. Zhang received a PhD from University of Maryland, College Park, in the field of synthetic organic chemistry and pursued postdoctoral research at University of California, Berkeley. He is an inventor on 24 US patents and patent applications.